Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet Oncology.[1] …
Continue reading →
The U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. It is the first new drug in decades to treat this type of cancer. …
Continue reading →
Picking the Cancer Treatment That Works Best for You- Ask the Expert about Personalized Medicine Live Web Chat with David Sidransky, MD, Johns Hopkins Medicine, Baltimore, MD, click here for bio Dr. David Sidransky is an award-winning oncologist and a world leading authority in the field of molecular diagnostics, targeted therapies and individualized patient treatments. [...]
According to a study presented at the 2011 European Multidisciplinary Cancer Congress, children born to women who received chemotherapy during pregnancy do not appear to have an increased risk of heart or cognitive problems. Since relatively few women are diagnosed with cancer during pregnancy, data regarding the effects of chemotherapy during pregnancy are limited. Determining [...]
The chemotherapy drug Halaven™ (eribulin mesylate) may be a promising therapy for certain types of soft-tissue sarcoma. These findings were recently reported in the Lancet Oncology. Halaven—which was derived from a marine sponge—is a chemotherapy drug that affects cell division. It was approved by the US Food and Drug Administration in November, 2010, for the treatment [...]
A large proportion of cancer patients do not enroll in clinical trials, and those who do participate may not adequately represent age groups, cancer stages, cancer types, and racial and ethnic groups. These findings were recently reported in the Annals of Surgery. Clinical trials are the process through which medications ultimately become approved by the [...]
A single dose of Kepivance® (palifermin) prior to each cycle of chemotherapy in sarcoma patients may substantially reduce the likelihood of moderate to severe mucositis. These findings from a randomized, double-blinded, placebo-controlled trial were recently published in the journal Annals of Internal Medicine.[1] Chemotherapy- or radiation-induced damage to the cells lining the mouth, throat, and [...]
A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases. These findings were recently published in the journal Cancer.[1] Lymphedema is the buildup of lymph fluid in the tissues just under the [...]
A new technique called regional hyperthermia (RHT) makes chemotherapy more effective and improves outcomes in patients with soft tissue sarcoma, according to the results of a study presented on September 22, 2009 at Europe’s largest cancer congress, ECCO 15-ESMO 34, in Berlin.[1] Soft tissue sarcomas are cancers that affect the connective and supportive tissues, which [...]
